147 related articles for article (PubMed ID: 16892169)
1. Multiple myeloma and B cell lymphoma. Investigation of IL-6, IL-6 receptor antagonist (IL-6RA), and GP130 antagonist (GP130A) using various parameters in an in vitro model.
Kovacs E
ScientificWorldJournal; 2006 Aug; 6():888-98. PubMed ID: 16892169
[TBL] [Abstract][Full Text] [Related]
2. How does interleukin-6 affect the membrane expressions of interleukin-6 receptor and gp130 and the proliferation of the human myeloma cell line OPM-2?
Kovacs E
Biomed Pharmacother; 2003 Dec; 57(10):489-94. PubMed ID: 14637393
[TBL] [Abstract][Full Text] [Related]
3. Cytostatic and cytocidal effects of mistletoe (Viscum album L.) quercus extract Iscador.
Kovacs E; Link S; Toffol-Schmidt U
Arzneimittelforschung; 2006 Jun; 56(6A):467-73. PubMed ID: 16927528
[TBL] [Abstract][Full Text] [Related]
4. Constitutive cytokine production by primary effusion (body cavity-based) lymphoma-derived cell lines.
Drexler HG; Meyer C; Gaidano G; Carbone A
Leukemia; 1999 Apr; 13(4):634-40. PubMed ID: 10214873
[TBL] [Abstract][Full Text] [Related]
5. Human herpesvirus type 8 interleukin-6 homologue is functionally active on human myeloma cells.
Burger R; Neipel F; Fleckenstein B; Savino R; Ciliberto G; Kalden JR; Gramatzki M
Blood; 1998 Mar; 91(6):1858-63. PubMed ID: 9490667
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-6 receptor antagonists inhibit interleukin-11 biological activity.
Sun RX; Gennaro C; Rocco S; Gu ZJ; Klein B
Eur Cytokine Netw; 1997 Mar; 8(1):51-6. PubMed ID: 9110148
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-6 leads to interleukin-10 production in several human multiple myeloma cell lines. Does interleukin-10 enhance the proliferation of these cells?
Kovacs E
Leuk Res; 2010 Jul; 34(7):912-6. PubMed ID: 19762082
[TBL] [Abstract][Full Text] [Related]
8. Comparative activity of Sant7 and anti-IL-6, IL-6R monoclonal antibodies in a murine model of B-cell lymphoma.
Campo S; Serlupi-Crescenzi O; Arseni B; Rossi S; Saggio I; Salone B; Cherubini G; Carminati P; De Santis R
Cytokine; 2005 Sep; 31(5):368-74. PubMed ID: 16061391
[TBL] [Abstract][Full Text] [Related]
9. Differential interleukin-6 (IL-6) responses of three established myeloma cell lines in the presence of soluble human IL-6 receptors.
Diamant M; Hansen MB; Rieneck K; Svenson M; Yasukawa K; Bendtzen K
Leuk Res; 1996 Apr; 20(4):291-301. PubMed ID: 8642840
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of myeloma cell growth by dexamethasone and all-trans retinoic acid: synergy through modulation of interleukin-6 autocrine loop at multiple sites.
Chen YH; Desai P; Shiao RT; Lavelle D; Haleem A; Chen J
Blood; 1996 Jan; 87(1):314-23. PubMed ID: 8547658
[TBL] [Abstract][Full Text] [Related]
11. Growth regulatory pathways in myeloma. Evidence for autocrine oncostatin M expression.
Westendorf JJ; Jelinek DF
J Immunol; 1996 Oct; 157(7):3081-8. PubMed ID: 8816418
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of interleukin-6-transsignaling via gp130-Fc in hemorrhagic shock and sepsis.
Mees ST; Toellner S; Marx K; Faendrich F; Kallen KJ; Schroeder J; Haier J; Kahlke V
J Surg Res; 2009 Dec; 157(2):235-42. PubMed ID: 19589542
[TBL] [Abstract][Full Text] [Related]
13. [Study on the biological activity and molecular mechanism of IFNalpha on human myeloma cell line Sko-007].
Song L; Li Y; Sun Y; Shen B
Zhonghua Xue Ye Xue Za Zhi; 2002 Oct; 23(10):517-9. PubMed ID: 12482347
[TBL] [Abstract][Full Text] [Related]
14. Resistance to interleukin 6 in human non-small cell lung carcinoma cell lines: role of receptor components.
Ganapathi MK; Weizer AK; Borsellino S; Bukowski RM; Ganapathi R; Rice T; Casey G; Kawamura K
Cell Growth Differ; 1996 Jul; 7(7):923-9. PubMed ID: 8809410
[TBL] [Abstract][Full Text] [Related]
15. Retinoic acid modulates the in vivo and in vitro growth of IL-6 autocrine human myeloma cell lines via induction of apoptosis.
Levy Y; Labaume S; Colombel M; Brouet JC
Clin Exp Immunol; 1996 Apr; 104(1):167-72. PubMed ID: 8603522
[TBL] [Abstract][Full Text] [Related]
16. Significance of autologous interleukin-6 production in the HA22T/VGH cell model of hepatocellular carcinoma.
Labbozzetta M; Notarbartolo M; Poma P; Giannitrapani L; Cervello M; Montalto G; D'Alessandro N
Ann N Y Acad Sci; 2006 Nov; 1089():268-75. PubMed ID: 17261774
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-6 controls recycling and degradation, but not internalization of its receptors.
Flynn CM; Kespohl B; Daunke T; Garbers Y; Düsterhöft S; Rose-John S; Haybaeck J; Lokau J; Aparicio-Siegmund S; Garbers C
J Biol Chem; 2021; 296():100434. PubMed ID: 33610555
[TBL] [Abstract][Full Text] [Related]
18. Analysis of IL-6-mediated growth control of myeloma cells using a gp130 chimeric receptor approach.
French JD; Tschumper RC; Jelinek DF
Leukemia; 2002 Jun; 16(6):1189-96. PubMed ID: 12040452
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of IL-6-dependent growth of myeloma cells by an acidic peptide repressing the gp130-mediated activation of Src family kinases.
Hausherr A; Tavares R; Schäffer M; Obermeier A; Miksch C; Mitina O; Ellwart J; Hallek M; Krause G
Oncogene; 2007 Jul; 26(34):4987-98. PubMed ID: 17310994
[TBL] [Abstract][Full Text] [Related]
20. Cooperation between heparin-binding EGF-like growth factor and interleukin-6 in promoting the growth of human myeloma cells.
Wang YD; De Vos J; Jourdan M; Couderc G; Lu ZY; Rossi JF; Klein B
Oncogene; 2002 Apr; 21(16):2584-92. PubMed ID: 11971193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
